Testing Pradaxa vs acetylsalicylic acid for preventing recurrent stroke misses its goal: Boehringer Ingelheim
Boehringer Ingelheim’s the trial did not meet its primary endpoint, which was to show aclinically significant difference between dabigatran etexilate and ASAon reducing the risk of a recurrent stroke among post-stroke patientswith ESUS.